Search Results - "Kump, Karson"

Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl‑1 and Bfl‑1 Proteins by Kump, Karson J, Miao, Lei, Mady, Ahmed S. A, Ansari, Nurul H, Shrestha, Uttar K, Yang, Yuting, Pal, Mohan, Liao, Chenzhong, Perdih, Andrej, Abulwerdi, Fardokht A, Chinnaswamy, Krishnapriya, Meagher, Jennifer L, Carlson, Jacob M, Khanna, May, Stuckey, Jeanne A, Nikolovska-Coleska, Zaneta

“…Anti-apoptotic Bcl-2 family proteins are overexpressed in a wide spectrum of cancers and have become well validated therapeutic targets. Cancer cells display…”
Get full text

Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening by Mady, Ahmed S. A., Liao, Chenzhong, Bajwa, Naval, Kump, Karson J., Abulwerdi, Fardokht A., Lev, Katherine L., Miao, Lei, Grigsby, Sierrah M., Perdih, Andrej, Stuckey, Jeanne A., Du, Yuhong, Fu, Haian, Nikolovska-Coleska, Zaneta

“…Protein-protein interactions (PPIs) represent important and promising therapeutic targets that are associated with the regulation of various molecular…”
Get full text

The effect of caffeine on skeletal muscle anabolic signaling and hypertrophy by Moore, Timothy M, Mortensen, Xavier M, Ashby, Conrad K, Harris, Alexander M, Kump, Karson J, Laird, David W, Adams, Aaron J, Bray, Jeremy K, Chen, Ting, Thomson, David M

“…Caffeine is a widely consumed stimulant with the potential to enhance physical performance through multiple mechanisms. However, recent in vitro findings have…”
Get more information

Abstract 324: BRAF/MEK inhibitors selectively prime melanoma for Mcl-1 dependence and sensitize to Mcl-1 inhibition by Kump, Karson J., Miao, Lei, Ansari, Nurul, Lombard, David B., Nikolovska-Coleska, Zaneta

“…Abstract Frontline treatment for patients diagnosed with metastatic melanoma harboring a V600 BRAF mutation is a combination of BRAF/MEK inhibitors. Despite…”
Get full text

AML-137: Preclinical Evaluation of Cytarabine and Venetoclax in Secondary AML by Foucar, Charles, Kump, Karson, Talpaz, Moshe, Bixby, Dale, Nikolovska-Coleska, Zaneta

“…Novel treatment approaches for patients with secondary acute myeloid leukemia (AML) are urgently needed. Secondary AML constitutes about 25-30% of AML and it…”
Get full text

Abstract LB-226: Discovery of small molecule Mcl-1 and Bfl-1 inhibitors by Kump, Karson J., Miao, Lei, Mady, Ahmed A., Ansari, Nurul H., Shrestha, Uttar K., Yang, Yuting, Pal, Mohan, Liao, Chenzhong, Perdih, Andrej, Abulwerdi, Fardokht A., Chinnaswamy, Krishnapriya, Meagher, Jennifer L., Carlson, Jacob M., Khanna, May, Stuckey, Jeanne A., Nikolovska-Coleska, Zaneta

“…Abstract Anti-apoptotic Bcl-2 family proteins are frequently overexpressed in various cancers and are established therapeutic targets. Cancer cells can either…”
Get full text

Abstract 10: Precision medicine strategy to elucidate and target Bcl-2 prosurvival proteins in a wide spectrum of cancers by Kump, Karson J., Lieberman, Matthew, Avelar, Rita A., Foucar, Charles, Kandarpa, Malathi, Di Cristofano, Antonio, Ryan, Russell J., Malek, Sami N., Wilcox, Ryan A., Bixby, Dale L., Phillips, Tycel J., Talpaz, Moshe, DiFeo, Analisa, Nikolovska-Coleska, Zaneta

“…Abstract Effective practice of precision medicine in oncology relies on identifying and targeting unique characteristics of individual cancers. Coupling…”
Get full text

Abstract 1970: Novel Mcl-1 inhibitor effectively restores in vivo regorafenib sensitivity in resistant colorectal cancer by Kump, Karson J., Tong, Jingshan, Mady, Ahmed S., Miao, Lei, Li, Siwei, Sun, Duxin, Yu, Jian, Zhang, Lin, Nikolovska-Coleska, Zaneta

“…Abstract Colorectal cancer (CRC) is one of deadliest malignancies and approximately 25% of patients present with metastatic disease at the time of diagnosis,…”
Get full text

Abstract 1173: A novel selective Mcl-1 inhibitor exhibits in vitro and in vivo efficacy in melanoma by Kump, Karson J., Miao, Lei, Mady, Ahmed S., Lev, Katherine, Giblin, William, Skinner, Mary E., Lombard, David B., Nikolovska-Coleska, Zaneta

“…Abstract Metastatic melanoma is the deadliest form of skin cancer that still has limited treatment options and dismal 5-year year survival rates as low as 15%…”
Get full text

Functional Elucidation and Targeting of the Bcl-2 Pro-Survival Proteins in Various Cancers by Kump, Karson J

“…Cancer is a heterogeneous group of diseases defined by distinct capabilities, including resistance to programmed cell death, or apoptosis. The Bcl-2 protein…”
Get full text

Abstract 5083: A novel and highly efficacious small-molecule degrader of BET-BRD proteins for the treatment of acute leukemia by Fernandez-Salas, Ester, Chen, Zhuo, Lin, Mei, Zhou, Bing, McEachern, Donna, Przybranowski, Sally, Kump, Karson, Peterson, Luke F., Kandarpa, Malathi, Hu, Jiantao, Xu, Fuming, Liu, Liu, Bai, Longchuan, Wen, Bo, Sun, Duxin, Talpaz, Moshe, Wang, Shaomeng

“…Abstract The bromodomain and extra-terminal domain (BET-BRD) family of lysine acetylation readers comprises BRD2, BRD3, BRD4, and BRDT that contain two…”
Get full text

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma by Phillips, Tycel J., Bond, David, Takiar, Radihka, Kump, Karson, Kandarpa, Malalthi, Boonstra, Philip, Mayer, Tera Lynn, Nachar, Victoria, Wilcox, Ryan A., Carty, Shannon A., Karimi, Yasmin H., Nikolovska-Coleska, Zaneta, Kaminski, Mark S., Herrera, Alex F., Maddocks, Kami, Popplewell, Leslie, Danilov, Alexey V.

“…•Venetoclax can be added to lenalidomide and rituximab without the occurrence of any dose-limiting toxicity in patients with untreated MCL.•Venetoclax and R2…”
Get full text